NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

Studying the clinical trial operation tells the story of the high risk that murcidencei is going to have a challenging regulator review process. Doesn't matter what the "science" is, or who ran the trial, the post hoc totally redone clinical trial design is enough to raise serious questions. Add the confounding of the naive OS (double dosing) and the FDA partial trial hold, and you have so many deficiencies in the trial, regulators are going to have serious issues.